Literature DB >> 22817868

Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Mohini Ranganathan1, Ashley Schnakenberg, Patrick D Skosnik, Bruce M Cohen, Brian Pittman, R Andrew Sewell, Deepak Cyril D'Souza.   

Abstract

BACKGROUND: Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults. Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens. However, there is little experimental data on the effects of SA in humans.
METHODS: In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiological, and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia.
RESULTS: SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting electroencephalogram spectral power. The SA administration was associated with a rapid increase of its levels in the blood. SA did not produce euphoria, cognitive deficits, or changes in vital signs. The effects were transient and not dose-related. SA administration was very well-tolerated without acute or delayed adverse effects.
CONCLUSIONS: SA produced a wide range of transient effects in healthy subjects. The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern. Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism. Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22817868      PMCID: PMC3638802          DOI: 10.1016/j.biopsych.2012.06.012

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  83 in total

1.  Effects of highly selective kappa-opioid agonists on EEG power spectra and behavioural correlates in conscious rats.

Authors:  C Coltro Campi; G D Clarke
Journal:  Pharmacol Biochem Behav       Date:  1995-08       Impact factor: 3.533

2.  Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia.

Authors:  A Maksimow; M Särkelä; J W Långsjö; E Salmi; K K Kaisti; A Yli-Hankala; S Hinkka-Yli-Salomäki; H Scheinin; S K Jääskeläinen
Journal:  Clin Neurophysiol       Date:  2006-06-27       Impact factor: 3.708

3.  Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Mauro Fà; Mario Manunta; Mara Puddu; Giampaolo Mereu; Gian Luigi Gessa
Journal:  Biol Psychiatry       Date:  2005-06-15       Impact factor: 13.382

4.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

Review 5.  Interactions between kappa opioid agonists and cocaine. Preclinical studies.

Authors:  N K Mello; S S Negus
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

9.  Cannabinoid modulations of resting state EEG θ power and working memory are correlated in humans.

Authors:  Koen B E Böcker; Claudine C Hunault; Jeroen Gerritsen; Maaike Kruidenier; Tjeert T Mensinga; J Leon Kenemans
Journal:  J Cogn Neurosci       Date:  2010-09       Impact factor: 3.225

10.  Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

Authors:  John E Mendelson; Jeremy R Coyle; Juan Carlos Lopez; Matthew J Baggott; Keith Flower; E Thomas Everhart; Thomas A Munro; Gantt P Galloway; Bruce M Cohen
Journal:  Psychopharmacology (Berl)       Date:  2010-12-08       Impact factor: 4.530

View more
  51 in total

1.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

2.  Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice.

Authors:  M Salaga; P R Polepally; M Zielinska; M Marynowski; A Fabisiak; N Murawska; K Sobczak; M Sacharczuk; J C Do Rego; B L Roth; J K Zjawiony; J Fichna
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

3.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

4.  μ and κ opioid receptor distribution in the monogamous titi monkey (Callicebus cupreus): implications for social behavior and endocrine functioning.

Authors:  B J Ragen; S M Freeman; S A Laredo; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2015-01-29       Impact factor: 3.590

5.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).

Authors:  B J Ragen; N Maninger; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2014-12-06       Impact factor: 3.590

9.  Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).

Authors:  Miguel Guerrero; Mariangela Urbano; Eun-Kyong Kim; Ana M Gamo; Sean Riley; Lusine Abgaryan; Nora Leaf; Lori Jean Van Orden; Steven J Brown; Jennifer Y Xie; Frank Porreca; Michael D Cameron; Hugh Rosen; Edward Roberts
Journal:  J Med Chem       Date:  2019-02-13       Impact factor: 7.446

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.